Roger Lehmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roger Lehmann has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
G. A. Spinas
Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich, Switzerland
3 shared publications- Philippe A. Gerber
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
3 shared publications Wolfgang Moritz
3 shared publicationsCharlotte Seer
Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich
2 shared publications- Jochen Seufert
Klinik für Innere Medizin II, Abteilung Endokrinologie und Diabetologie, Universitätsklinikum Freiburg, Freiburg, Germany
2 shared publications M. Weber
University Hospital Zurich, Islet Transplant Program
2 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Springer Nature in Die Diabetologie
- Vol. 22 (3) , 241
Erratum zu: Perioperatives Management von Menschen mit Diabetes mellitus: Diabetologie
- 23 February 2026
- Published by Springer Nature in Die Diabetologie
- Vol. 22 (3) , 241
Open AccessErratum zu: Perioperatives Management von Menschen mit Diabetes mellitus: Diabetologie
- Open Access
- 5 August 2025
- Published by Springer Nature in Die Diabetologie
- Vol. 22 (2) , 88-95
Perioperatives Management von Menschen mit Diabetes mellitus: Diabetologie
Zusammenfassung: Das optimale Management von Patienten mit Diabetes während der perioperativen Periode erfordert eine interprofessionelle Kommunikation und Organisation der Pflege durch Ärzte verschiedener Fachrichtungen. Ziel ist es, Komplikationen zu verhindern, den klinischen Endpunkt zu verbessern und die Patientenzufriedenheit zu stärken. Es muss ein strukturierter Behandlungsplan erstellt werden, der alle entscheidenden Phasen der Hospitalisierung von der Zuweisung bis zur Entlassung in die ambulante Betreuung umfasst. Schon nach der Zuweisung sollte festgelegt werden, wann und welche antidiabetischen Medikamente abgesetzt werden sollen. Der optimale Zielbereich der Glukose intraoperativ beträgt 8–10 mmol/l (140–180 mg/dl) und ist damit etwas höher angesetzt als normalerweise während einer Hospitalisierung (5,6–10,0 mmol/l [100–180 mg/dl]). Dadurch werden gefährliche Hypoglykämien vermieden. Beim Management müssen der Diabetestyp geklärt und die Länge der vorgesehenen Operation sowie die Insulintherapie genau geplant werden. Postoperativ ist es wichtig, die Art der Ernährung (parenterale, enterale Ernährung, Nahrungsaufbau) und die damit verbundene Insulintherapie (i.v. mit Perfusor oder subkutan) genau aufeinander abzustimmen. Bei der Entlassung aus dem Krankenhaus sollte die medikamentöse Behandlungsstrategie festgelegt werden, und eine Diabetesfachperson sollte gewährleisten, dass der Patient und seine Familie diese verstehen und umsetzen können. Es sollte ein Nachfolgetermin beim behandelnden Hausarzt oder Endokrinologen innerhalb von 1 Monat nach der Entlassung stattfinden, und es sollte sichergestellt werden, dass der Patient alle Medikamente und notwendiges medizinisches Material bis zur Kontrolle beim nachbehandelnden Arzt in seinem Besitz hat.
- 5 August 2025
- Published by Springer Nature in Die Diabetologie
- Vol. 22 (2) , 88-95
Open AccessPerioperatives Management von Menschen mit Diabetes mellitus: Diabetologie
Zusammenfassung: Das optimale Management von Patienten mit Diabetes während der perioperativen Periode erfordert eine interprofessionelle Kommunikation und Organisation der Pflege durch Ärzte verschiedener Fachrichtungen. Ziel ist es, Komplikationen zu verhindern, den klinischen Endpunkt zu verbessern und die Patientenzufriedenheit zu stärken. Es muss ein strukturierter Behandlungsplan erstellt werden, der alle entscheidenden Phasen der Hospitalisierung von der Zuweisung bis zur Entlassung in die ambulante Betreuung umfasst. Schon nach der Zuweisung sollte festgelegt werden, wann und welche antidiabetischen Medikamente abgesetzt werden sollen. Der optimale Zielbereich der Glukose intraoperativ beträgt 8–10 mmol/l (140–180 mg/dl) und ist damit etwas höher angesetzt als normalerweise während einer Hospitalisierung (5,6–10,0 mmol/l [100–180 mg/dl]). Dadurch werden gefährliche Hypoglykämien vermieden. Beim Management müssen der Diabetestyp geklärt und die Länge der vorgesehenen Operation sowie die Insulintherapie genau geplant werden. Postoperativ ist es wichtig, die Art der Ernährung (parenterale, enterale Ernährung, Nahrungsaufbau) und die damit verbundene Insulintherapie (i.v. mit Perfusor oder subkutan) genau aufeinander abzustimmen. Bei der Entlassung aus dem Krankenhaus sollte die medikamentöse Behandlungsstrategie festgelegt werden, und eine Diabetesfachperson sollte gewährleisten, dass der Patient und seine Familie diese verstehen und umsetzen können. Es sollte ein Nachfolgetermin beim behandelnden Hausarzt oder Endokrinologen innerhalb von 1 Monat nach der Entlassung stattfinden, und es sollte sichergestellt werden, dass der Patient alle Medikamente und notwendiges medizinisches Material bis zur Kontrolle beim nachbehandelnden Arzt in seinem Besitz hat.
- 29 July 2025
- Published by Springer Nature
- p. 77-88
Diabetes Mellitus
- 4 April 2024
- Published by Springer Nature
- p. 79-91
Diabetes mellitus
- 25 October 2022
- Published by Springer Nature in Die Diabetologie
- Vol. 18 (7) , 775-777
Wiederherstellung der endogenen Insulinsekretion – Utopie oder Realität?
- 25 October 2022
- Published by Springer Nature in Die Diabetologie
- Vol. 18 (7) , 775-777
Wiederherstellung der endogenen Insulinsekretion – Utopie oder Realität?
- Open Access
- 23 October 2017
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-12
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent comorbidities in patients with T2D, accounting for 50% of mortality. Following recent CV outcomes trial (CVOT) results, including those from EMPA-REG OUTCOME®, LEADER®, SUSTAIN™-6 and, most recently, the CANVAS study, it is essential to develop regional expert consensus recommendations to aid physicians in interpreting these newest data to clinical practice. The Central and Eastern European Diabetes Expert Group (CEEDEG) followed a Delphi method to develop treatment algorithms to aid physicians in the clinical management of patients with T2D at high CV risk. In light of the latest CVOT results, and in particular the EMPA-REG OUTCOME® and LEADER® trials, the diagnosis, assessment, treatment choice and monitoring of patients with T2D and established CVD and/or CKD have been considered together with existing guidelines and presented in two reference algorithms. In addition, adherence, special prescribing considerations and a proposed multidisciplinary management approach have been discussed and are presented with the proposed algorithms. The latest available high-level evidence on glucose-lowering drugs has enabled CEEDEG to develop practical consensus recommendations for patients with established CVD and/or CKD. These recommendations represent an update to international and country-level guidelines used for these patients, with the aim of providing a resource not only to endocrinologists, but to cardiologists, nephrologists and primary care physicians in the region.
- 23 October 2017
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-12
Open AccessTranslating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent comorbidities in patients with T2D, accounting for 50% of mortality. Following recent CV outcomes trial (CVOT) results, including those from EMPA-REG OUTCOME®, LEADER®, SUSTAIN™-6 and, most recently, the CANVAS study, it is essential to develop regional expert consensus recommendations to aid physicians in interpreting these newest data to clinical practice. The Central and Eastern European Diabetes Expert Group (CEEDEG) followed a Delphi method to develop treatment algorithms to aid physicians in the clinical management of patients with T2D at high CV risk. In light of the latest CVOT results, and in particular the EMPA-REG OUTCOME® and LEADER® trials, the diagnosis, assessment, treatment choice and monitoring of patients with T2D and established CVD and/or CKD have been considered together with existing guidelines and presented in two reference algorithms. In addition, adherence, special prescribing considerations and a proposed multidisciplinary management approach have been discussed and are presented with the proposed algorithms. The latest available high-level evidence on glucose-lowering drugs has enabled CEEDEG to develop practical consensus recommendations for patients with established CVD and/or CKD. These recommendations represent an update to international and country-level guidelines used for these patients, with the aim of providing a resource not only to endocrinologists, but to cardiologists, nephrologists and primary care physicians in the region.
- 1 February 2016
- Published by Hogrefe Publishing Group in Praxis
- Vol. 105 (3) , 171
CME-Antworten zu den Fragen zu «Antidiabetika bei Niereninsuffizienz und Nierentransplantation» aus Praxis Nr. 2
- 1 February 2016
- Published by Hogrefe Publishing Group in Praxis
- Vol. 105 (3) , 171
CME-Antworten zu den Fragen zu «Antidiabetika bei Niereninsuffizienz und Nierentransplantation» aus Praxis Nr. 2
- 1 January 2016
- Published by Hogrefe Publishing Group in Praxis
- Vol. 105 (2) , 69-76
CME: Antidiabetika bei Niereninsuffizienz und Nierentransplantation
- 1 January 2016
- Published by Hogrefe Publishing Group in Praxis
- Vol. 105 (2) , 69-76
CME: Antidiabetika bei Niereninsuffizienz und Nierentransplantation
- Open Access
- 22 October 2015
- Published by Springer Nature in Der Diabetologe
- Vol. 11 (7) , 534-537
β-Zell-Ersatz-Therapie
- 22 October 2015
- Published by Springer Nature in Der Diabetologe
- Vol. 11 (7) , 534-537
Open Accessβ-Zell-Ersatz-Therapie
- 16 April 2014
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 11 (1) , 109-120
Improved physiological properties of gravity-enforced reassembled rat and human pancreatic pseudo-islets
Previously we demonstrated the superiority of small islets vs large islets in terms of function and survival after transplantation, and we generated reaggregated rat islets (pseudo-islets) of standardized small dimensions by the hanging-drop culture method (HDCM). The aim of this study was to generate human pseudo-islets by HDCM and to evaluate and compare the physiological properties of rat and human pseudo-islets. Isolated rat and human islets were dissociated into single cells and incubated for 6–14 days by HDCM. Newly formed pseudo-islets were analysed for dimensions, morphology, glucose-stimulated insulin secretion (GSIS) and total insulin content. The morphology of reaggregated human islets was similar to that of native islets, while rat pseudo-islets had a reduced content of α and δ cells. GSIS of small rat and human pseudo-islets (250 cells) was increased up to 4.0-fold (p < 0.01) and 2.5-fold (p < 0.001), respectively, when compared to their native counterparts. Human pseudo-islets showed a more pronounced first-phase insulin secretion as compared to intact islets. GSIS was inversely correlated to islet size, and small islets (250 cells) contained up to six-fold more insulin/cell than large islets (1500 cells). Tissue loss with this new technology could be reduced to 49.2 ± 1.5% in rat islets, as compared to the starting amount. With HDCM, pseudo-islets of standardized size with similar cellular composition and improved biological function can be generated, which compensates for tissue loss during production. Transplantation of small pseudo-islets may represent an attractive strategy to improve graft survival and function, due to better oxygen and nutrient supply during the phase of revascularization. Copyright © 2014 John Wiley & Sons, Ltd.
- 16 April 2014
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 11 (1) , 109-120
Improved physiological properties of gravity-enforced reassembled rat and human pancreatic pseudo-islets
Previously we demonstrated the superiority of small islets vs large islets in terms of function and survival after transplantation, and we generated reaggregated rat islets (pseudo-islets) of standardized small dimensions by the hanging-drop culture method (HDCM). The aim of this study was to generate human pseudo-islets by HDCM and to evaluate and compare the physiological properties of rat and human pseudo-islets. Isolated rat and human islets were dissociated into single cells and incubated for 6–14 days by HDCM. Newly formed pseudo-islets were analysed for dimensions, morphology, glucose-stimulated insulin secretion (GSIS) and total insulin content. The morphology of reaggregated human islets was similar to that of native islets, while rat pseudo-islets had a reduced content of α and δ cells. GSIS of small rat and human pseudo-islets (250 cells) was increased up to 4.0-fold (p < 0.01) and 2.5-fold (p < 0.001), respectively, when compared to their native counterparts. Human pseudo-islets showed a more pronounced first-phase insulin secretion as compared to intact islets. GSIS was inversely correlated to islet size, and small islets (250 cells) contained up to six-fold more insulin/cell than large islets (1500 cells). Tissue loss with this new technology could be reduced to 49.2 ± 1.5% in rat islets, as compared to the starting amount. With HDCM, pseudo-islets of standardized size with similar cellular composition and improved biological function can be generated, which compensates for tissue loss during production. Transplantation of small pseudo-islets may represent an attractive strategy to improve graft survival and function, due to better oxygen and nutrient supply during the phase of revascularization. Copyright © 2014 John Wiley & Sons, Ltd.